FTC Requests Public Comment on Application from Grifols, S.A. to Amend Contract Manufacturing Agreement that was part of 2011 Divestiture Ordered by the Agency

The Federal Trade Commission is currently accepting public comments on an application by Grifols, S.A., a manufacturer of plasma-derived drugs, to amend the terms of a manufacturing agreement that was part of a 2011 FTC-ordered divestiture. The order settled charges that Grifols’ $3.4 billion acquisition of competitor Talecris Biotherapeutics Holdings Corp. was anticompetitive. Under the […]